ATE461705T1 - Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose - Google Patents

Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose

Info

Publication number
ATE461705T1
ATE461705T1 AT98930483T AT98930483T ATE461705T1 AT E461705 T1 ATE461705 T1 AT E461705T1 AT 98930483 T AT98930483 T AT 98930483T AT 98930483 T AT98930483 T AT 98930483T AT E461705 T1 ATE461705 T1 AT E461705T1
Authority
AT
Austria
Prior art keywords
artheriosclerosis
prevent
magnesium absorption
increase magnesium
magnesium
Prior art date
Application number
AT98930483T
Other languages
English (en)
Inventor
Michael W Dixon
Original Assignee
Michael W Dixon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael W Dixon filed Critical Michael W Dixon
Application granted granted Critical
Publication of ATE461705T1 publication Critical patent/ATE461705T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98930483T 1997-06-27 1998-06-25 Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose ATE461705T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/883,287 US5849337A (en) 1997-06-27 1997-06-27 Method of enhancing magnesium absorption and prevention of atherosclerosis
PCT/US1998/013098 WO1999000015A1 (en) 1997-06-27 1998-06-25 Method of enhancing magnesium absorption and prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE461705T1 true ATE461705T1 (de) 2010-04-15

Family

ID=25382325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930483T ATE461705T1 (de) 1997-06-27 1998-06-25 Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose

Country Status (8)

Country Link
US (1) US5849337A (de)
EP (1) EP1003370B1 (de)
JP (1) JP3622985B2 (de)
AT (1) ATE461705T1 (de)
AU (1) AU7986798A (de)
CA (1) CA2295108C (de)
DE (1) DE69841573D1 (de)
WO (1) WO1999000015A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372264B1 (en) * 2000-08-24 2002-04-16 Gusty Winds Corporation Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
US8017160B2 (en) 2003-08-15 2011-09-13 Russell Jaffe Enhancement of magnesium uptake in mammals
CA2532161A1 (en) * 2003-09-05 2005-03-17 Matthias Rath Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
KR101483207B1 (ko) * 2014-06-25 2015-01-22 한국지질자원연구원 고흡수성 마그네슘 복합체의 제조방법
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
US11344575B2 (en) 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
EP4236699A4 (de) 2020-10-28 2024-07-17 Balchem Corporation Verfahren zur erhöhung der bioverfügbarkeit und absorption von magnesium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167562A (en) * 1978-08-28 1979-09-11 Evers H Ray Method and composition for treating arteriosclerosis
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US5162344A (en) * 1987-05-04 1992-11-10 Robert Koch Procaine double salt complexes
DE3938992A1 (de) * 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
GB2306109B (en) * 1997-02-07 1997-09-24 John Wright A zinc containing composition as a common cold prophylactic

Also Published As

Publication number Publication date
AU7986798A (en) 1999-01-19
WO1999000015A1 (en) 1999-01-07
JP3622985B2 (ja) 2005-02-23
EP1003370A1 (de) 2000-05-31
JP2001506277A (ja) 2001-05-15
DE69841573D1 (de) 2010-05-06
EP1003370A4 (de) 2004-04-21
US5849337A (en) 1998-12-15
CA2295108A1 (en) 1999-01-07
EP1003370B1 (de) 2010-03-24
CA2295108C (en) 2004-06-01

Similar Documents

Publication Publication Date Title
GT199800126A (es) Terapia de combinacion.
ES2172944T3 (es) Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
AP9801392A0 (en) Concentrated antibody preparation.
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
NL300258I2 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van.
IL124536A0 (en) A glycine uptake antagonist
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
FI950169L (fi) PTH:n ja PTHRP:n analogit, niiden synteesi ja käyttö osteoporoosin hoitoon
ATE63813T1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
ATE461705T1 (de) Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
KR100292396B1 (de)
EP0479600A3 (en) Delivery of agents
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
AU9363398A (en) Hepatitis c receptor protein cd81
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
MY108692A (en) Topical composition
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
PL328948A1 (en) Autism treating method
MX9804343A (es) Aplicacion dirigida de dosificaciones de agentes medicinales y terapeuticos y otros glicosaminoglicanos (gags).
PL328924A1 (en) Method of treating abuse of substances
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties